Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie's acquisition of ImmunoGen leading the charge in 2023, and Merck's licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.

Even Eli Lilly's acquisition of Mablink, despite lacking clinical programs, underscores the feverish pace of activity in the field, breaking traditional pharma partnering trends.

For ADC companies, the challenge lies in standing out, validating their offerings, and securing clinical-ready assets amidst this whirlwind of activity.

URLs:

Tickets: https://go.evvnt.com/2481194-2?pid=91 

Brochure: https://go.evvnt.com/2481194-3?pid=91 

Prices:

Two Day Attendance and Access to Partnering Portal - Biotech, Pharma and Investors: USD 2999.00,

Two Day Attendance and Access to Partnering Portal - Academics: USD 2399.00

Speakers: Adrianne Wong, Director, Oncology Search and Evaluation, Global Business Development, Daiichi Sankyo, Albert Hsia, Executive Director, Business Development, Merck, Avnish Kapoor, Executive Director, Search and Evaluation, Oncology Business Development, BMS, Andressa Smith, Senior Director, Scientific Licensing and Acquisition, Oncology Business Development, Johnson and Johnson, Carlos Loya, Venture Partner, 82VS, Christopher Davies, Business Development Project Leader, Genentech, Chris O’Donnell, Vice President Business Development, Pfizer, Claire Leurent, Managing Director, AbbVie Ventures, Cookie Yu, Investment Director, Samsung Venture Investment Corporation, David Dowling, Global Search and Evaluation Lead, Oncology Strategy, Roche, Greg Dwyer, Vice President, Head of Business Development, Orum Therapeutics, Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Harris Weber, Principal, Bain Capital Life Sciences, He Tian, Associate Director of External Innovations, BioNTech, Ingo Lehrke, Chief Business Officer, Tubulis, Isan Chen, Co-founder, President and Chief Executive Officer, Mbrace Therapeutics, Jenny Wang, Director Search and Evaluation, Oncology, AbbVie, John Flygare, Co-Founder, Chief Scientific Officer, Firefly Bio, Joey Xiao, Co-founder and Chief Operating Officer, MediLink Therapeutics, Laura Collins, Senior Director, Transactions, Business Development, AstraZeneca, Kalyan Chakravarthy, Associate Director, External Innovation, Ipsen, Masashi Shimazaki, Senior Director, Primary Focus Area Targeted Protein Degradation, Portfolio Strategy Lead, Astellas Pharma, Marc Robillard, Chief Executive Officer and Founder, Tagworks Pharmaceuticals, Natalia Ulyanova, Business Development Director, Oncology, Astellas Pharma, Melissa Conner, Senior Director of Business Development, Acquisitions and Licensing, Janssen Pharmaceuticals, Nicki Vasquez, Chief Portfolio Strategy and Alliance Officer, Sutro Biopharma, Neil Bander, Founder, Chief Scientific Officer, Convergent Therapeutics, Patrick Zweidler-McKay, Executive Medical Director, AbbVie, Owen Dempsey, Chief Executive Officer, Avipep Therapeutics, Sophie Brachet, Head of Early Commercial and Access, Debiopham International, Ramon Valencia, Vice President, Business Development, SystImmune, Venky Raghavan, Executive Director Search and Evaluation Oncology, Novartis, Steve Bartz, Head of Oncology Business Development, Search and Evaluation, Pfizer, Shailee Patel, Scientific Liaison Analyst, Beacon by Hanson Wade, Liat Izhak, Director, Search and Evaluation, Business Development, Genmab